ATE279937T1 - Fgf-2 angiogenische wirksame einheitdosis und ihrer verwendung - Google Patents

Fgf-2 angiogenische wirksame einheitdosis und ihrer verwendung

Info

Publication number: ATE279937T1
Authority: AT; Austria
Prior art keywords: present; fgf; directed; unit dose; another aspect
Prior art date: 1998-09-03

Application number

AT99968630T

Other languages

English (en)

Inventor

Martha Jo Whitehouse

Original Assignee

Chiron Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-03

Filing date

1999-08-27

Publication date

2004-11-15

1999-08-27 Application filed by Chiron Corp filed Critical Chiron Corp

2004-11-15 Application granted granted Critical

2004-11-15 Publication of ATE279937T1 publication Critical patent/ATE279937T1/de

Links

102000003974 Fibroblast growth factor 2 Human genes 0.000 title abstract 4
108090000379 Fibroblast growth factor 2 Proteins 0.000 title abstract 4
230000002491 angiogenic effect Effects 0.000 title abstract 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 2
208000029078 coronary artery disease Diseases 0.000 abstract 2
239000012634 fragment Substances 0.000 abstract 2
229960002897 heparin Drugs 0.000 abstract 2
229920000669 heparin Polymers 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
108010045614 CAD trifunctional enzyme Proteins 0.000 abstract 1
210000004351 coronary vessel Anatomy 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
239000012530 fluid Substances 0.000 abstract 1
238000001802 infusion Methods 0.000 abstract 1
230000002093 peripheral effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
210000003462 vein Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Heart & Thoracic Surgery (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)

AT99968630T 1998-09-03 1999-08-27 Fgf-2 angiogenische wirksame einheitdosis und ihrer verwendung ATE279937T1 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US14574398P	1998-09-03	1998-09-03
US10410298P	1998-10-13	1998-10-13
US10410398P	1998-10-13	1998-10-13
PCT/US1999/019770 WO2000013701A2 (en)	1998-09-03	1999-08-27	Angiogenically effective unit dose of fgf-2 and method of use

Publications (1)

Publication Number	Publication Date
ATE279937T1 true ATE279937T1 (de)	2004-11-15

Family

ID=27379656

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT04018831T ATE434440T1 (de)	1998-09-03	1999-08-27	Fgf-2 angiogenische wirksame einheitdosis und verfahren zu ihrer verwendung
AT99968630T ATE279937T1 (de)	1998-09-03	1999-08-27	Fgf-2 angiogenische wirksame einheitdosis und ihrer verwendung

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT04018831T ATE434440T1 (de)	1998-09-03	1999-08-27	Fgf-2 angiogenische wirksame einheitdosis und verfahren zu ihrer verwendung

Country Status (7)

Country	Link
EP (2)	EP1121142B1 (de)
JP (2)	JP5329729B2 (de)
AT (2)	ATE434440T1 (de)
AU (1)	AU6022399A (de)
DE (2)	DE69941034D1 (de)
ES (2)	ES2327839T3 (de)
WO (1)	WO2000013701A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1121141A2 (de)	1998-10-13	2001-08-08	Chiron Corporation	Fgf angiogenische wirksäme einheitdosis und verfahren zür ihre verwendung
US20020072489A1 (en) *	1998-10-13	2002-06-13	Whitehouse Martha J.	Angiogenically effective unit dose of FGF-2 and method of use
US8618052B2 (en)	1998-10-13	2013-12-31	Novartis Vaccines And Diagnostics, Inc.	Method of treating coronary artery disease by administering FGF-5
JP5704780B2 (ja)	1999-08-13	2015-04-22	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	脈管形成因子の用量および心筋血流を改善するための投与方法
US20020032153A1 (en) *	2000-03-10	2002-03-14	Whitehouse Martha Jo	Methods and compositions for the treatment and prevention of erectile dysfunction
US20020115603A1 (en) *	2000-06-22	2002-08-22	Chiron Corporation	Methods and compositions for the treatment of peripheral artery disease
EP1894570A3 (de) *	2000-06-22	2009-11-11	Novartis Vaccines and Diagnostics, Inc.	Verfahren und Zusammensetzungen zur Behandlung von Erkrankungen der peripheren Arterie
PE20110891A1 (es)	2008-12-09	2011-12-23	Pfizer Vaccines Llc	Vacuna de peptido ch3 de ige
US20200384079A1 (en) *	2017-04-26	2020-12-10	University Of Cincinnati	Compositions of Fibroblast Growth Factor LIgands and Methods of Treating Patients Undergoing Ischemia-Reperfusion Therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5155214A (en)	1984-03-05	1992-10-13	The Salk Institute For Biological Studies	Basic fibroblast growth factor
US4956455A (en)	1984-03-05	1990-09-11	The Salk Institute For Biological Studies	Bovine fibroblast growth factor
US4959314A (en)	1984-11-09	1990-09-25	Cetus Corporation	Cysteine-depleted muteins of biologically active proteins
US5439818A (en)	1985-09-12	1995-08-08	Scios Nova Inc.	DNA encoding human recombinant basic fibroblast growth factor
DE3689845T3 (de) *	1985-09-12	2001-11-15	Scios Inc., Sunnyvale	Rekombinanter fibroblast-wachstumsfaktor.
US5852177A (en) *	1987-02-24	1998-12-22	Takeda Chemical Industries, Ltd.	Basic fibroblast growth factor (bFGF) muteins

1999
- 1999-08-27 DE DE69941034T patent/DE69941034D1/de not_active Expired - Lifetime
- 1999-08-27 ES ES04018831T patent/ES2327839T3/es not_active Expired - Lifetime
- 1999-08-27 ES ES99968630T patent/ES2233101T3/es not_active Expired - Lifetime
- 1999-08-27 WO PCT/US1999/019770 patent/WO2000013701A2/en not_active Ceased
- 1999-08-27 EP EP99968630A patent/EP1121142B1/de not_active Expired - Lifetime
- 1999-08-27 AT AT04018831T patent/ATE434440T1/de not_active IP Right Cessation
- 1999-08-27 DE DE69921348T patent/DE69921348T2/de not_active Expired - Lifetime
- 1999-08-27 AU AU60223/99A patent/AU6022399A/en not_active Abandoned
- 1999-08-27 JP JP2000568509A patent/JP5329729B2/ja not_active Expired - Lifetime
- 1999-08-27 EP EP09161208.5A patent/EP2123292B1/de not_active Expired - Lifetime
- 1999-08-27 AT AT99968630T patent/ATE279937T1/de not_active IP Right Cessation
2010
- 2010-04-08 JP JP2010089915A patent/JP2010163457A/ja active Pending

Also Published As

Publication number	Publication date
EP2123292B1 (de)	2016-05-04
WO2000013701A9 (en)	2000-10-05
DE69941034D1 (de)	2009-08-06
JP2010163457A (ja)	2010-07-29
WO2000013701A3 (en)	2000-08-03
EP1121142A2 (de)	2001-08-08
DE69921348D1 (de)	2004-11-25
HK1075409A1 (en)	2005-12-16
JP5329729B2 (ja)	2013-10-30
WO2000013701A2 (en)	2000-03-16
JP2002524420A (ja)	2002-08-06
ES2327839T3 (es)	2009-11-04
DE69921348T2 (de)	2006-02-09
ES2233101T3 (es)	2005-06-01
ATE434440T1 (de)	2009-07-15
EP1121142B1 (de)	2004-10-20
EP2123292A1 (de)	2009-11-25
AU6022399A (en)	2000-03-27

Legal Events

Date	Code	Title	Description
2005-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
PT710114E (pt)	2003-06-30	Formulacao do factor viii de coagulacao
WO2000021548A3 (en)	2000-08-31	Angiogenically effective unit dose of fgf and method of administering
WO2001098346A3 (en)	2003-05-01	Methods and compositions for the treatment of peripheral artery disease
NZ283499A (en)	1997-08-22	Haemophilia medicament; comprises coagulation factor viii or factor ix
IL135712A (en)	2010-12-30	Use of recombinant activated protein c in the manufacture of medicaments for treating or preventing acquired hypercoagulable states associated with sepsis
WO2002058720A3 (en)	2003-05-15	Angiogenically effective unit dose of fgf-2 and method of use
ATE279937T1 (de)	2004-11-15	Fgf-2 angiogenische wirksame einheitdosis und ihrer verwendung
GB9023701D0 (en)	1990-12-12	Medical treatment
JP2002524420A5 (de)	2006-09-14
Lund-Olesen et al.	1983	Intra-articular orgotein therapy in osteoarthritis of the knee. A double-blind, placebo-controlled trial
US4150119A (en)	1979-04-17	Method for treatment of vascular disease
EP1894570A3 (de)	2009-11-11	Verfahren und Zusammensetzungen zur Behandlung von Erkrankungen der peripheren Arterie